Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TOPIRAMATE

All products: general benefit

Other products in the same Health Canada class (N03AX) — coverage varies; not interchangeable

  • Lamotrigine (Lamictal): general benefit
  • Brivaracetam (Brivlera): limited Use 548
  • Cenobamate (Xcopri): limited Use 719
  • Lacosamide (Vimpat): limited Use 430
  • Levetiracetam (PDP-Levetiracetam): limited Use 473, Limited Use 640, 705
  • Perampanel (Fycompa): limited Use 430, 564

14 more in the class list below

Topamax · DIN 02230896 · 200mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-24 — choose a marketed DIN from the same-category list.Discontinued 2026-07-24 · checked 2026-09-20
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-24 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Topamax · DIN 02230896 Manufacturer: Janssen-Ortho Inc.; listing date 1998-12-31 Health Canada: Cancelled post market since 2026-07-24 · brand TOPAMAX 200MG · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 200 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.6748 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50174 · Verify on the e-Formulary ↗ (DIN 02230896)

Source record
DIN 02230896: Topamax Raw flags: sec3=Y Item: 281200071; group id 446; item number 1118; lccId None; manufacturer id JNO Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $6.5235; ministry $0.6748 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230896 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50174
Interchangeable products
Ach-Topiramate · DIN 02395754 · $0.6748 Apo-Topiramate · DIN 02279649 · $0.6748 Auro-Topiramate · DIN 02345846 · $0.6748 Jamp Topiramate Tablets · DIN 02345277 · $0.6748 Jamp-Topiramate · DIN 02435624 · $0.6748 Mar-Topiramate · DIN 02432110 · $0.6748 Mint-Topiramate · DIN 02315661 · $0.6748 Mylan-Topiramate · DIN 02263386 · $0.6748 NRA-Topiramate · DIN 02538474 · $0.6748 PMS-Topiramate · DIN 02263017 · $0.6748 Ran-Topiramate · DIN 02396092 · $0.6748 Sandoz Topiramate Tablets · DIN 02431823 · $0.6748 Teva-Topiramate · DIN 02248862 · $0.6748 Topiramate · DIN 02356872 · $0.6748 Topiramate · DIN 02553880 · $0.6748
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-07-24 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, VALPROIC ACID 28:12 Anticonvulsants

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit)

LACOSAMIDE

· 44 products · Limited Use, codes 430 · strengths: 50mg, 100mg, 150mg, 200mg · Tab

LEVETIRACETAM

· 49 products · Limited Use, codes 640, 705 (3), Limited Use, codes 473 (46) · strengths: 100mg/mL, 250mg, 500mg, 750mg, 1000mg · Oral Sol, Tab

PERAMPANEL

· 12 products · Limited Use, codes 430, 564 · strengths: 2mg, 4mg, 6mg, 8mg, 10mg, 12mg · Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications Epilepsy TOPAMAX® (topiramate) is indicated: • as monotherapy for the management of patients (adults and children six years and older) with newly diagnosed epilepsy. • as adjunctive therapy for the management of patients (adults and children two years and older) with epilepsy who are not satisfactorily controlled with conventional therapy. Migraine Prophylaxis Topamax is indicated in adults for the prophylaxis of migraine headache. Prophylactic treatment of migraine may be considered in situations such as: adults experiencing four or more migraine attacks per month who fail to respond adequately to acute abortive therapy; recurring attacks that significantly interfere with the patient’s daily routine; a pattern of increasing migraine attacks over time, with the risk of developing rebound headache from acute abortive therapies; or failure of, or contraindication to, or troublesome side effects from acute abortive medications. Continuing therapy should be reviewed every six months. Topamax should not be used in the acute treatment of migraine attacks. Safety and efficacy of topiramate in the management or prevention of cluster headache… https://pdf.hres.ca/dpd_pm/00081153.PDF PM date: 2025-07-23 Source product: TOPAMAX; DIN 02239907; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.